I’m not sure what to make of this announcement. We’re in the business of developing MDMA like compounds for therapeutic use, yet we’ve just gone and bought some from a supplier and it seems like we’re going to move into more of an enabler type role than as a supplier ourselves.
Its a little confusing and I guess the concern is with what about all the companies research and development? Does the rescheduling mean “MDMA LIKE” research is not necessary now as actual MDMA is now going to be available?
Please note I sold last week on the hype, until the pathway became clearer for commercial opportunities. It’s exciting but I’m not sure where we fit into this market right now.
Add to My Watchlist
What is My Watchlist?
